The Global Rheumatoid Arthritis Drugs Market was valued at US$ 24.7 Bn in 2020 is expected to reach US$ 35.0 Bn by 2027, with a growing CAGR of 5.1% during the forecast period (2021-2027).
Rheumatoid Arthritis (RA) is a chronic inflammatory disorder. This disorder affects joints such as skin, eyes, lungs heart and other body parts. This is also known as an autoimmune disorder. Rheumatoid arthritis affects the lining of joints which ultimately leads to swelling in bones. However, ongoing research and new medicinal treatments prove to be beneficial for treating rheumatoid arthritis. Rheumatoid arthritis is a progressive disorder that progresses to severe along time if kept untreated. This disorder progresses along with age, mostly 35-50 years of age.
Rheumatoid Arthritis (RA) is a chronic inflammatory disorder. This disorder affects joints such as skin, eyes, lungs heart and other body parts. This is also known as autoimmune disorder. Rheumatoid arthritis affects the lining of joints which ultimately leads to swelling in bones. However, ongoing research and new medicinal treatments prove to be beneficial for treating rheumatoid arthritis. Rheumatoid arthritis is a progressive disorder which progresses to sever along time if kept untreated. This disorder progresses along with age, mostly 35-50 years of age.
According to the survey, out of 100,000 people, 71 are diagnosed with rheumatoid arthritis every year. In U.S., more than 1.5 million Americans are diagnosed with rheumatoid arthritis. Women are more prone to get RA than men due to difference in hormonal levels. Rheumatoid arthritis affects all populations; however, the severity is much more is some groups of population such as 4-7% in Native Americans and lower in Caribbean region population. Rise in incidence of disorder drives the Rheumatoid Arthritis Drugs market.
New approvals for rheumatoid arthritis, rise in prevalence of the disorder, expiration of patents, new drugs in pipeline, increase in geriatric population are expected to drive the growth of Rheumatoid Arthritis drugs market. Moreover, rapid rise in research technologies, government initiatives, introduction, and acceptance of biosimilars for the treatment, rise in healthcare expenditure and increase in awareness about disorder and available treatments further triggers the growth of the Rheumatoid Arthritis drugs market.
Rheumatoid Arthritis Drugs Segmentation:
Company Profiles and Competitive Intelligence
The key players operating in the market are:
The unique insights provided by this report also includes the following:
Based on drug class, disease-modifying anti-rheumatic drugs held a dominant position in 2020 and is expected to maintain same during forecast period.
On the basis of drug class, rheumatoid arthritis is broadly segmented into DMARs, NSAID’s, corticosteroids, and uric acid drugs. DMARD’s prove to be major contributor in the growth of RA drug market due to the increase in development and demand of use of DMARD’s, rise in prevalence in RA, increase in over-weighted population and unhealthy environment. DMARD’s is one of the first line treatment for rheumatoid arthritis and this boost the growth of segment in rheumatoid arthritis drugs market.
Moreover, increase in use of NSAID’s compel the rise in the production of medication and prove to have increase in demand and supply during forecast period. According to the survey, increase in number of RA cases drives the growth of NSAID’s in the RA market.
Based on sales channel, prescription-based drugs had maximum market share in 2020.
Depending upon sales channel, rheumatoid arthritis is segmented into prescription-based and over-the-counter based segments. Prescription based sales channel is expected to have the highest market share during the forecast period. This is due to the advantages provided by this segment includes prescribing the correct dose, the availability of historical data of patients and helps to prevent misuse of drugs. These factors drive the growth of this segment in the rheumatoid arthritis drugs market. However, the OTC-based sales channel is expected to show fastest growth during forecast period due to increase in convince of ease of purchase and upcoming innovations in OTC- drugs
Based on geographical region, Asia-Pacific projected to exhibit the highest growth in CAGR during forecast period.
On the basis of region, Asia-Pacific is witnessed to exhibit the highest growth during forecast period. This is due to increase in number of key players followed by increasing population. Other factors that contribute to the growth of this region include increase in awareness regarding use of and benefits of drugs, availability of early diagnostics, rising government funding in research and development process, increase in healthcare expenditure and rise in disposable. Moreover, low manufacturing cost and facilities in developing countries like India and China drives the growth of the rheumatoid arthritis drugs market.
The report also provides in-depth analysis of Rheumatoid Arthritis Drugs dynamics such as drivers, restraints opportunities and challenges
COVID-19 Impact on the Rheumatoid Arthritis Drugs Market Analysis
Covid-19 has highly affected the industries in terms of growth, economy, health, and mental wellbeing of every individual. In this challenging situation, every industry is trying to give best services in terms of quality and safety. Covid –19 has affected more than 200 countries across the globe. According to the scientist and physicians, patients with RA and infected with virus have high risk of developing severity and complications. Certain category of drugs such as DMARD’s are used both in RA as well as found to be effective in Covid-19 treatment. This boosts the growth opportunities of manufactures of RA drugs during the forecast period. On-going research on RA drugs such as baricitinib for the treatment of covid-19, if proved to be effective, will drive the growth of RA drugs market during forecast period.
The report also provides an in-depth analysis of key trends
|1||Covid –19 prove to have positive impact on RA drug market due to common use of medication of RA and covid treatment like DMARD, drives the growth of the market.||Positive|
|2||Supportive governments initiatives and development of innovative biosimilar therapies||Positive|
The report also provides in-depth analysis of recent news developments and investments
Ask for free product review call with the author
Share your specific research requirements for a customized report
Request for due diligence and consumer centric studies
Request for study updates, segment specific and country level reports